Business Description
![Agios Pharmaceuticals Inc Agios Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C0000A59D.png?14)
Agios Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00847X1046
Share Class Description:
AGIO: Ordinary SharesCompare
Compare
Traded in other countries / regions
AGIO.USA0HB0.UK8AP.GermanyAGIO.Mexico IPO Date
2013-07-24Description
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.75 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.18 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 11.92 | |||||
Beneish M-Score | -2.27 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -13.5 | |||||
3-Year EPS without NRI Growth Rate | -9.9 | |||||
3-Year FCF Growth Rate | -8.6 | |||||
3-Year Book Growth Rate | 36 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 37.59 | |||||
9-Day RSI | 47.65 | |||||
14-Day RSI | 53.47 | |||||
6-1 Month Momentum % | 70.29 | |||||
12-1 Month Momentum % | 32.96 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.84 | |||||
Quick Ratio | 12.39 | |||||
Cash Ratio | 11.57 | |||||
Days Inventory | 2136.75 | |||||
Days Sales Outstanding | 28.47 | |||||
Days Payable | 1346.67 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 6.9 | |||||
Shareholder Yield % | 0.54 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 89.95 | |||||
Operating Margin % | -1336.42 | |||||
Net Margin % | -1199.26 | |||||
FCF Margin % | -1084.88 | |||||
ROE % | -39.69 | |||||
ROA % | -35.05 | |||||
ROIC % | -136.94 | |||||
ROC (Joel Greenblatt) % | -432.26 | |||||
ROCE % | -41.34 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 81.96 | |||||
PB Ratio | 3.29 | |||||
Price-to-Tangible-Book | 3.29 | |||||
EV-to-EBIT | -4.88 | |||||
EV-to-Forward-EBIT | -0.81 | |||||
EV-to-EBITDA | -4.96 | |||||
EV-to-Revenue | 65.23 | |||||
EV-to-Forward-Revenue | 35.28 | |||||
EV-to-FCF | -6.01 | |||||
Price-to-Net-Current-Asset-Value | 4.39 | |||||
Price-to-Net-Cash | 4.97 | |||||
Earnings Yield (Greenblatt) % | -20.49 | |||||
FCF Yield % | -13.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AGIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agios Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 29.403 | ||
EPS (TTM) ($) | -6.32 | ||
Beta | 0.36 | ||
Volatility % | 54.31 | ||
14-Day RSI | 53.47 | ||
14-Day ATR ($) | 1.802746 | ||
20-Day SMA ($) | 45.219 | ||
12-1 Month Momentum % | 32.96 | ||
52-Week Range ($) | 19.795 - 49.055 | ||
Shares Outstanding (Mil) | 56.77 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Agios Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Agios Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Agios Pharmaceuticals Inc Frequently Asked Questions
What is Agios Pharmaceuticals Inc(AGIO)'s stock price today?
The current price of AGIO is $43.11. The 52 week high of AGIO is $49.06 and 52 week low is $19.80.
When is next earnings date of Agios Pharmaceuticals Inc(AGIO)?
The next earnings date of Agios Pharmaceuticals Inc(AGIO) is 2024-08-02 Est..
Does Agios Pharmaceuticals Inc(AGIO) pay dividends? If so, how much?
Agios Pharmaceuticals Inc(AGIO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |